The White Plague was tuberculosis, a bacterial lung disease that earned its grim nickname from the ghostly pallor it gave its victims as they slowly wasted away. During the eighteenth and nineteenth centuries, TB killed roughly one in four Europeans, making it the single deadliest infectious disease of the industrialized world. The name distinguished it from the “Black Plague” of medieval memory, and it stuck in popular culture long after scientists identified the bacterium responsible. The story of TB stretches far deeper than the Victorian era, though, running from ancient bones to a pathogen that still kills well over a million people a year.
An Ancient Disease Written in Bone
TB is not a modern affliction. The bacterium Mycobacterium tuberculosis has left traces in human remains spanning thousands of years. The most recognizable skeletal signature is Pott’s disease, a destruction of the vertebrae that produces a characteristic hunchback deformity. Other bone changes, like lesions on the ribs, are less specific but still point investigators toward the diagnosis.1PubMed Central. The Evolution of Diagnostic Techniques in the Paleopathology of Tuberculosis: A Scoping Review Most of this skeletal evidence comes from northern-hemisphere sites, with the strongest archaeological record concentrated in late medieval Europe, roughly the twelfth through sixteenth centuries, though earlier evidence exists from the Near East and Egypt.2PubMed. Old World tuberculosis: Evidence from human remains with a review of current research and future prospects
In recent decades, researchers have moved beyond bones. Ancient DNA techniques now allow scientists to detect and even fully reconstruct TB genomes from mummified or skeletal remains. Early work relied on targeting specific repetitive genetic elements of the Mycobacterium tuberculosis complex; newer high-throughput sequencing has made it possible to recover complete ancient genomes.3PubMed. Tuberculosis in mummies – New findings, perspectives and limitations These ancient genomes have helped settle a major question about the pathogen’s age. Analysis of a seventeenth-century TB genome, combined with molecular-clock modeling, places the most recent common ancestor of the entire Mycobacterium tuberculosis complex somewhere between roughly 2,200 and 4,500 years before present, consistent with a Neolithic emergence that tracks the rise of settled agriculture and denser human populations.4PubMed Central. A seventeenth-century Mycobacterium tuberculosis genome supports a Neolithic emergence of the Mycobacterium tuberculosis complex
Why “The White Plague”
By the 1700s and into the 1800s, TB was ravaging European cities in a way that felt inescapable. The disease killed slowly, over months or years. Victims grew emaciated, their skin turning pale and almost translucent as fever consumed them from within. In an era before germ theory, people attributed the disease to bad air, heredity, or temperament. Romantic poets and composers famously died of it, lending consumption a perverse cultural glamor: the wan, feverish artist became a literary archetype. But the reality was industrial and brutal. Overcrowded tenements, malnutrition, and poorly ventilated workplaces turned cities into breeding grounds. Nobody understood why households would lose member after member to the same wasting illness, because the idea that invisible organisms could pass between people had not yet taken hold.
The name “White Plague” captured both the pallor and the scale. TB was a plague not in the sudden, explosive sense of bubonic outbreaks but in the grinding, demographic sense. It was always there, always killing, always filling the charity wards. In some European cities during the peak decades, TB mortality rates exceeded those of every other known cause of death. The slow, visible deterioration of its victims, combined with the sheer volume of death, gave the disease a cultural presence that shaped art, architecture, and eventually public health policy.
Koch and the Germ
The turning point in understanding TB came on March 24, 1882, when the German physician Robert Koch presented his discovery of the tubercle bacillus to the Berlin Physiological Society. After centuries of speculation about whether consumption might be infectious, Koch proved conclusively that a specific micro-organism caused the disease, one he had isolated and grown in pure culture.5PubMed Central. Robert koch: centenary of the discovery of the tubercle bacillus, 1882 The discovery earned him a Nobel Prize and transformed TB from a mysterious wasting condition into a potentially controllable infection.
Koch also introduced tuberculin, a preparation derived from the bacterium that he initially hoped would be a cure. It was not. But tuberculin proved valuable as a diagnostic tool, forming the basis of the skin test still used today to detect TB exposure.6PubMed Central. Robert Koch: centenary of the discovery of the tubercle bacillus, 1882 Koch’s work also revealed that human and bovine strains of TB were distinct, an insight that would become critical for food safety. The identification of the pathogen did not immediately save lives, but it gave public health authorities something they had never had: a rational basis for prevention. If TB was caused by a germ that spread through the air, then isolation, ventilation, and hygiene could, in principle, slow it down.
Sanatoria and Collapse Therapy
Without drugs to kill the bacterium, the late nineteenth and early twentieth centuries saw the rise of the sanatorium as the primary institutional response to TB. From the mid-1800s through the mid-1900s, sanatoria spread across Europe and North America. The philosophy was simple: fresh air, rest, balanced nutrition, and graduated physical exercise in an open-air setting. Beyond the health regimen, sanatoria served a critical public health function by isolating contagious patients from the general population, which remained one of the most effective measures for limiting transmission.7PubMed Central. The history of tuberculosis: the social role of sanatoria for the treatment of tuberculosis in Italy between the end of the 19th century and the middle of the 20th
For patients whose disease was progressing despite the sanatorium regimen, physicians turned to something more radical: collapse therapy. The Italian physician Carlo Forlanini pioneered artificial pneumothorax in the late nineteenth century, a procedure in which air was injected into the chest cavity to deliberately collapse the diseased lung. The logic was that a collapsed lung could not expand, which limited oxygen supply to the bacteria and allowed damaged tissue to rest and scar over. The procedure was crude by modern standards and uncomfortable for patients, but it remained widely used for decades in the pre-antibiotic era.8PubMed Central. Carlo Forlanini, inventor of artificial pneumothorax for treatment of pulmonary tuberculosis Surgical variations included removing ribs (thoracoplasty) to permanently compress the lung. These operations were desperate measures, and many patients did not survive them, but in an era with no antibiotics, they represented the best available option for advanced pulmonary TB.
How TB Actually Works Inside the Body
To understand why TB was so hard to fight, it helps to know what the bacterium does once inhaled. When Mycobacterium tuberculosis reaches the lungs, the immune system responds by walling it off inside a structure called a granuloma, a tight cluster of immune cells that surrounds and contains the bacteria. In most people, the granuloma succeeds in holding the infection in check indefinitely. This is latent TB: the person is infected but not sick and not contagious.
The trouble is that the granuloma is not just a prison for the bacterium. It is also a survival niche. The bacteria can persist inside granulomas for years or decades, sheltered from both immune attack and antibiotics. If the immune system weakens for any reason, the granuloma can break down. In active TB, the bacterium drives the immune response to such an extreme that the granuloma’s center dies and liquefies, eventually eroding into the airways. This is how TB becomes contagious: the dead tissue, packed with bacteria, is coughed up and expelled as airborne droplets.9PubMed Central. The granuloma in tuberculosis: dynamics of a host-pathogen collusion The bacterium, in a grim evolutionary sense, engineers its own transmission by provoking the very immune destruction that opens its route to new hosts.
BCG and the Vaccine That Half Worked
The only TB vaccine in widespread use, Bacille Calmette-Guérin (BCG), traces back to work begun in 1908 by Albert Calmette and Camille Guérin, who spent thirteen years painstakingly weakening a live bovine TB strain through repeated laboratory passages until it could no longer cause disease. The attenuated bacterium was first given to a human infant in 1921. It proved safe and modestly protective, and governments gradually adopted it into childhood immunization programs.10The Microbe. Factors influencing the efficacy of Bacille Calmette-Guérin (BCG) vaccine
Today, 156 of 194 countries include neonatal BCG vaccination in their public health programs.10The Microbe. Factors influencing the efficacy of Bacille Calmette-Guérin (BCG) vaccine But BCG’s effectiveness remains genuinely controversial. The vaccine is good at preventing severe forms of TB in young children, particularly the disseminated and meningeal types that kill infants. It is far less reliable at preventing pulmonary TB in adults, which is the form responsible for ongoing transmission. Study after study has found wildly variable protection rates depending on geography, population, and which BCG sub-strain was used.11PubMed Central. History of BCG Vaccine Part of the problem is that the original BCG strain was shipped to laboratories around the world, where it continued to change genetically under different growth conditions. These sub-strains now differ in colony appearance, the proteins they produce, and their ability to stimulate immune responses in infants.10The Microbe. Factors influencing the efficacy of Bacille Calmette-Guérin (BCG) vaccine The World Health Organization eventually stipulated that BCG strains used for mass production should not undergo more than twelve laboratory passages, to prevent further genetic drift. Even so, the world has been working with a vaccine of limited and variable efficacy for over a century.
Antibiotics Change Everything
The real revolution came in 1944, when streptomycin became the first antibiotic shown to be effective against Mycobacterium tuberculosis. The drug was developed in the laboratory of Selman Waksman, who had been systematically screening soil microorganisms for antibacterial compounds. A submerged culture technique enabled large-scale streptomycin production, which in turn made rapid animal testing and human clinical trials possible.12PubMed Central. Selman A. Waksman, winner of the 1952 Nobel Prize for physiology or medicine Waksman received the Nobel Prize for the discovery in 1952.
Streptomycin’s success launched a wave of drug development. By the 1960s, physicians had isoniazid, pyrazinamide, rifampicin, and ethambutol, the backbone of modern TB treatment. Multi-drug regimens proved far more effective than any single antibiotic, because the bacterium readily develops resistance when attacked on only one front. Standard first-line treatment today still involves a combination of four drugs taken for six months, a length dictated by the slow-growing nature of the bacterium and the difficulty of reaching bacteria hidden inside granulomas. TB treatment was never easy or short, but antibiotics transformed a disease with a case fatality rate approaching fifty percent into one that could be cured in the vast majority of patients who completed therapy.
Mass Screening and the Glasgow Experiment
Alongside antibiotics, public health campaigns focused on finding and treating cases before they could spread. Chest X-ray screening became a powerful tool in the mid-twentieth century. One of the most dramatic demonstrations of its impact occurred in Glasgow in 1957, when the city launched a mass screening campaign. Over about five weeks, roughly 715,000 people were screened using miniature chest X-rays, covering about 76% of the city’s adult population. The campaign diagnosed roughly 2,400 cases, a huge spike in detection. In the years that followed, the city’s annual rate of new pulmonary TB notifications fell faster than it would have otherwise, with an estimated 4,600 cases averted between 1958 and 1963, a reduction of about 43% beyond what would have occurred without the intervention.13PLOS Medicine. Impact of active case finding for tuberculosis with mass chest X-ray screening in Glasgow, Scotland, 1950–1963: An epidemiological analysis of historical data Glasgow’s experience showed that aggressively finding and treating cases could bend the curve of TB transmission at a population level.
The Deadly Partnership With HIV
By the 1980s, TB was receding in wealthy nations and some public health officials spoke optimistically about eventual eradication. Then HIV arrived. The collision between TB and HIV was catastrophic, particularly in sub-Saharan Africa. HIV is the single most powerful known risk factor for progressing from latent TB infection to active disease, increasing the risk of reactivation roughly 20-fold.14PubMed Central. Tuberculosis and HIV co-infection In return, TB became the most common cause of AIDS-related death. The two pathogens work in synergy: HIV destroys the very immune cells that hold TB in check inside granulomas, while active TB accelerates HIV replication and speeds the collapse of the immune system.15PubMed. Bird’s Eye View on Mycobacterium tuberculosis-HIV Coinfection: Understanding the Molecular Synergism, Challenges, and New Approaches to Therapeutics
The HIV epidemic essentially reversed decades of TB progress in the hardest-hit regions, driving case counts and death rates back up to levels not seen in a generation. Managing both infections simultaneously remains clinically challenging because of drug interactions, overlapping side effects, and the need to rebuild a shattered immune system while also killing a slow-growing bacterium hiding inside lung tissue.
Drug Resistance and the Rise of Superbugs
TB’s other modern crisis is drug resistance. Mycobacterium tuberculosis mutates slowly compared to many bacteria, but the long treatment courses give resistance ample opportunity to develop, especially when patients take drugs inconsistently, when drug supply chains are interrupted, or when health systems prescribe inadequate regimens. Multidrug-resistant TB (MDR-TB) is defined by resistance to at least isoniazid and rifampicin, the two most powerful first-line drugs. Extensively drug-resistant TB (XDR-TB) adds resistance to key second-line agents on top of that.
Whole-genome sequencing of outbreak strains has revealed how resistance accumulates in stepwise fashion over decades. In one well-studied epidemic in KwaZulu-Natal, South Africa, researchers traced the buildup of resistance mutations across roughly fifty years. The ancestral strain first acquired isoniazid and streptomycin resistance around 1957, gained MDR-level resistance around 1984 through additional mutations affecting rifampicin and pyrazinamide, and reached XDR status by approximately 1995 through mutations conferring resistance to kanamycin and ofloxacin.16PLoS Medicine. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal By the time the Tugela Ferry XDR-TB outbreak gained international attention in 2005, the strain had been accumulating resistance for nearly half a century. The episode illustrated a sobering reality: resistance does not appear overnight but is built layer by layer, and by the time it becomes clinically visible, it may already be deeply entrenched in circulating strains.
Modern Diagnostics and the GeneXpert Revolution
For most of TB’s history, diagnosis was slow. Traditional culture methods, where a sputum sample is grown on a special medium to see if TB bacteria appear, can take weeks. Smear microscopy, in which a technician looks at sputum under a microscope to spot the bacteria directly, is faster but misses a substantial fraction of cases, especially in people with HIV who tend to have fewer bacteria in their sputum.
The introduction of the GeneXpert MTB/RIF assay, endorsed by the World Health Organization in December 2010, marked a paradigm shift. The test uses molecular technology to detect both TB and rifampicin resistance from a single sputum sample in under two hours, directly at the point of care.17PubMed Central. Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control In field evaluations, adding molecular testing to standard microscopy increased the sensitivity of TB diagnosis from roughly 74% to about 88%, with the biggest gains coming among patients whose initial microscopy result was negative.18PubMed Central. Performance and impact of GeneXpert MTB/RIF® and Loopamp MTBC Detection Kit® assays on tuberculosis case detection in Madagascar Faster, more accurate diagnosis means faster treatment initiation, which in turn means less time for an infectious patient to spread the disease.
TB in 2024 and the Unfinished Fight
Despite everything, Mycobacterium tuberculosis remains the leading single-pathogen killer on earth. In 2024, an estimated 10.7 million people developed TB, and the disease caused roughly 1.23 million deaths, including about 150,000 among people living with HIV. About a quarter of the world’s population carries immunological evidence of past or current infection.19PubMed. State of the global tuberculosis epidemic: burden, progress towards WHO End TB Strategy targets and systemic challenges Thirty high-burden countries account for 87% of cases, led by India, Indonesia, the Philippines, China, Pakistan, Nigeria, the Democratic Republic of the Congo, and Bangladesh.
Progress is happening, but it is painfully slow. Global incidence declined about 1% from 2023 to 2024, which sounds modest and is. Three years of COVID-19-related disruptions set back TB control significantly, and case rates remain higher than they were in 2020. Case detection improved to about 8.3 million notifications, which represents roughly 78% of estimated cases, meaning more than one in five people with TB are still going undiagnosed. Of the estimated 390,000 MDR or rifampicin-resistant cases in 2024, only 42% started treatment, though success rates among those treated improved to 71%.19PubMed. State of the global tuberculosis epidemic: burden, progress towards WHO End TB Strategy targets and systemic challenges Global financing for TB programs reached only 27% of what is needed.
Milk, Cattle, and Zoonotic TB
The White Plague was not exclusively a human-to-human story. For centuries, bovine TB, caused by the closely related Mycobacterium bovis, jumped from cattle to people, primarily through unpasteurized milk. In nineteenth-century Europe and North America, when bovine TB was rampant and pasteurization did not exist, children were disproportionately affected because they were the primary milk consumers and their immune systems were still developing.20PubMed Central. Zoonotic Tuberculosis and Dairy Products: Comprehensive Meta‐Analysis of Prevalence and Public Health Implications The introduction of milk pasteurization and livestock testing-and-slaughter programs in the twentieth century dramatically reduced zoonotic TB in wealthy countries. In much of the developing world, however, bovine TB in livestock persists, and consumption of raw or fermented dairy products remains common, keeping this transmission route open.
Human Genetics and Why Some People Resist
One of the underappreciated chapters in TB’s history concerns why some people who are heavily exposed never get sick, while others rapidly progress to severe disease. Part of the answer is clearly environmental: nutrition, housing conditions, and co-infections like HIV all matter enormously. But human genetic variation also plays a significant role. Resistance to Mycobacterium tuberculosis infection has a strong genetic component, shaped by thousands of years of co-evolution between the pathogen and human populations.21PubMed Central. Co-evolution of Mycobacterium tuberculosis and Homo sapiens Populations that experienced sustained TB pressure over many generations, particularly in urban Europe and parts of Asia, may carry higher frequencies of resistance-associated genetic variants simply because susceptible individuals died before reproducing. Populations with less historical exposure, such as some indigenous communities first encountering TB through colonization, have often suffered devastating outbreaks. Researchers have also found that the interaction is not one-directional: specific human genetic variants interact with specific TB lineages, suggesting that pathogen and host have been shaping each other’s evolution in a long, ongoing arms race.
The Next Generation of Vaccines
After a century with only BCG, the TB vaccine landscape is finally changing. As of mid-2026, 18 TB vaccine candidates are in clinical development, representing the most diverse and advanced pipeline since BCG was first introduced.22The Lancet Infectious Diseases. What Was the White Plague? A History of Tuberculosis These span multiple technological platforms, including protein subunit vaccines, viral-vectored vaccines, whole-cell mycobacterial vaccines, and mRNA-based approaches.23PubMed. Toward tuberculosis elimination: An update on tuberculosis vaccines in clinical trials Some are designed to replace BCG in newborns. Others aim to boost protection in adolescents and adults, the group that drives transmission but gets the least benefit from BCG. A few target people with latent TB infection, with the goal of preventing reactivation. The M72/AS01E candidate made headlines a few years ago after a phase IIb trial showed it cut the rate of active TB roughly in half among latently infected adults. Larger confirmatory trials are underway. If any of these candidates reaches licensure and widespread use, it would be the single biggest advance in TB prevention in over a hundred years.